Abstract:Key Points Parkinson's disease is a progressive neurological disorder characterized primarily by motor symptoms that include rigidity, hypokinesia and tremor. The most pronounced neuropathological feature is a loss of dopaminergic neurons in the substantia nigra pars compacta, which leads to a reduction in dopamine levels in the target region, the striatum. In the substantia nigra, some neurons have intracytoplasmic inclusions known as Lewy bodies. In most patients, Parkinson's disease shows no clear inheritance and the cause of neurodegeneration is not known. Several disease mechanisms have been proposed, including oxidative stress and mitochondrial dysfunction. Some emphasis has been placed on the possibility that environmental toxins trigger these pathological changes. In the late 1990s, the discovery of the gene that causes a rare autosomal-dominant form of Parkinson's disease led to renewed interest in the search for pathogenic mechanisms. The mutated gene encodes α-synuclein, a synaptic protein of unknown function. It has been suggested that it plays a role in the recycling of vesicles that have released their neurotransmitter content into the synaptic cleft. Moreover, further rare forms of Parkinson's disease have been identified that result from mutations in parkin and ubiquitin carboxy-terminal hydrolase L1. These proteins participate in the ubiquitin–proteasome pathway, which is responsible for the degradation of unwanted proteins. We speculate why changes in these diverse genes lead to a neurodegenerative process that is relatively focused on dopamine-containing neurons, and emphasize the role of dopamine-dependent oxidative stress in this process. We believe that there are multiple aetiological triggers, resulting from either genetic changes or environmental insults, which share the same final common pathway to cell death in dopaminergic neurons. Increased levels of cytoplasmic dopamine in nigral neurons in Parkinson's disease patients might result in dopamine oxidation and the generation of reactive oxygen species that can damage and eventually kill these neurons. One pathway that might lead to these events involves impaired vesicular storage of dopamine. Recent experimental evidence shows that the expression of mutant α-synuclein in a human dopaminergic cell line increases cytoplasmic dopamine levels and raises the levels of superoxide radicals in the cytoplasm. Dopamine-induced oxidative stress, impaired synaptic vesicle function and misfolding of α-synuclein, due to mutations or to oxidative damage to this protein, might be components in a self-perpetuating vicious cycle that eventually leads to the demise of dopaminergic neurons.

[Alpha-synuclein interacted proteins: the relevance with the pathogenesis of Parkinson's disease].

Structure, Distribution, and Genetic Profile of Α-Synuclein and Their Potential Clinical Application in Parkinson's Disease.

Protein–protein interactions regulating α-synuclein pathology

Identification of novel proteins associated with both alpha-synuclein and DJ-1.

Identification of novel proteins interacting with both α-synuclein and DJ-1

Alpha-Synuclein Aggregation in Parkinson's Disease

Exploring α-synuclein Interaction Partners and their Potential Clinical Implications for Parkinson's Disease

alpha-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease

The interaction between alpha-synuclein and mitochondrial dysfunction in Parkinson's disease

Interplay between α-synuclein and parkin genes: Insights of Parkinson's disease

Physiological and Pathological Functions of Neuronal Hemoglobin: A Key Underappreciated Protein in Parkinson’s Disease

Role of microglial activation induced by α-synuclein in pathogenesis of Parkinson's disease

The Role of α-Synuclein Oligomers in Parkinson’s Disease

Prion-Like Mechanisms in Parkinson’s Disease

Aggregation and phase separation of α-synuclein in Parkinson's disease

Pathogenesis of parkinson's disease: dopamine, vesicles and α-synuclein

alpha-synuclein, autophagy-lysosomal pathway, and Lewy bodies: mutations, propagation, aggregation, and the formation of inclusions

α-Synuclein as a Diagnostic Marker and Therapeutic Target for Parkinson Disease

Synergy between plasminogen activator inhibitor-1, α-synuclein, and neuroinflammation in Parkinson's disease

Hypoxia and Alpha-Synuclein: Inextricable Link Underlying the Pathologic Progression of Parkinson's Disease

Initiation and propagation of α-synuclein aggregation in the nervous system